BRPI0616447A2 - complexo de inclusão de carbamazepina-ciclodextrina, método de administrar e método de preparar o mesmo - Google Patents

complexo de inclusão de carbamazepina-ciclodextrina, método de administrar e método de preparar o mesmo Download PDF

Info

Publication number
BRPI0616447A2
BRPI0616447A2 BRPI0616447-1A BRPI0616447A BRPI0616447A2 BR PI0616447 A2 BRPI0616447 A2 BR PI0616447A2 BR PI0616447 A BRPI0616447 A BR PI0616447A BR PI0616447 A2 BRPI0616447 A2 BR PI0616447A2
Authority
BR
Brazil
Prior art keywords
carbamazepine
cyclodextrin
cbz
administration
complex
Prior art date
Application number
BRPI0616447-1A
Other languages
English (en)
Portuguese (pt)
Inventor
James Cloyd
Angela Birnbaum
Ilo Leppik
Stephen Collins
Original Assignee
Ovation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37906812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0616447(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ovation Pharmaceuticals Inc filed Critical Ovation Pharmaceuticals Inc
Publication of BRPI0616447A2 publication Critical patent/BRPI0616447A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0616447-1A 2005-09-30 2006-10-02 complexo de inclusão de carbamazepina-ciclodextrina, método de administrar e método de preparar o mesmo BRPI0616447A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72269205P 2005-09-30 2005-09-30
US60/722.692 2005-09-30
PCT/US2006/038508 WO2007041524A2 (en) 2005-09-30 2006-10-02 Novel parenteral carbamazepine formulation

Publications (1)

Publication Number Publication Date
BRPI0616447A2 true BRPI0616447A2 (pt) 2011-06-21

Family

ID=37906812

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616447-1A BRPI0616447A2 (pt) 2005-09-30 2006-10-02 complexo de inclusão de carbamazepina-ciclodextrina, método de administrar e método de preparar o mesmo

Country Status (18)

Country Link
US (3) US20070185054A1 (enExample)
EP (2) EP1928464B1 (enExample)
JP (2) JP5284096B2 (enExample)
CN (1) CN101309691A (enExample)
AU (1) AU2006299501B2 (enExample)
BR (1) BRPI0616447A2 (enExample)
CA (1) CA2624463C (enExample)
CY (1) CY1115517T1 (enExample)
DK (1) DK1928464T3 (enExample)
ES (2) ES2475157T3 (enExample)
MX (1) MX2008004287A (enExample)
NZ (1) NZ567290A (enExample)
PL (1) PL1928464T3 (enExample)
PT (1) PT1928464E (enExample)
RU (2) RU2455996C2 (enExample)
SI (1) SI1928464T1 (enExample)
WO (1) WO2007041524A2 (enExample)
ZA (1) ZA200803332B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
RU2464042C1 (ru) * 2011-03-31 2012-10-20 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
US20140178479A1 (en) 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US11235020B2 (en) * 2013-03-13 2022-02-01 Abraham Palmer Methods and compositions for inhibiting glyoxalase 1 (GLO1)
CN105726466A (zh) * 2014-12-10 2016-07-06 辽宁药联制药有限公司 一种奥卡西平注射剂及其制备方法
MY200159A (en) * 2016-12-14 2023-12-09 Sk Biopharmaceuticals Co Ltd Parenteral liquid preparation comprising carbamate compound
WO2020157257A1 (en) * 2019-02-01 2020-08-06 H. Lundbeck A/S Injectable carbamazepine composition essentially free of 10-br-carbamazepine
US12383633B1 (en) 2024-10-01 2025-08-12 Zymeron Corporation Injectable formulations of PARP inhibitors and uses thereof
CN120754274A (zh) * 2025-07-15 2025-10-10 江苏鹏鹞药业有限公司 一种卡马西平的生产工艺及负载分散剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5231098A (en) * 1987-06-26 1993-07-27 Nihon Bayer Agrochem K.K. Insecticidal nitro-substituted heterocyclic compounds
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6546131B1 (en) 1990-12-19 2003-04-08 Canon Kabushiki Kaisha Image processing method and apparatus for achieving tone reproduction suited to the image
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2713934B1 (fr) 1993-12-22 1996-01-12 Commissariat Energie Atomique Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives.
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
GB9721497D0 (en) 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
AU772204B2 (en) 1999-01-21 2004-04-22 Bristol-Myers Squibb Company Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
JP2006509788A (ja) 2002-11-27 2006-03-23 ファルマシア・コーポレーション バルデコキシブの濃縮液体組成物

Also Published As

Publication number Publication date
JP5794966B2 (ja) 2015-10-14
ES2708375T3 (es) 2019-04-09
WO2007041524A3 (en) 2007-09-13
EP1928464B1 (en) 2014-05-14
CA2624463A1 (en) 2007-04-12
AU2006299501A1 (en) 2007-04-12
US20070185054A1 (en) 2007-08-09
JP2013040195A (ja) 2013-02-28
DK1928464T3 (da) 2014-06-23
AU2006299501A2 (en) 2008-05-08
ZA200803332B (en) 2011-05-25
EP2444090A1 (en) 2012-04-25
US20220265547A1 (en) 2022-08-25
RU2012112839A (ru) 2013-10-10
WO2007041524A2 (en) 2007-04-12
JP5284096B2 (ja) 2013-09-11
RU2455996C2 (ru) 2012-07-20
US20240165125A1 (en) 2024-05-23
CY1115517T1 (el) 2017-01-04
ES2475157T3 (es) 2014-07-10
EP1928464A2 (en) 2008-06-11
RU2008117161A (ru) 2009-11-10
SI1928464T1 (sl) 2014-09-30
NZ567290A (en) 2011-08-26
AU2006299501B2 (en) 2012-11-29
CA2624463C (en) 2017-02-14
PL1928464T3 (pl) 2014-10-31
EP2444090B1 (en) 2018-12-12
JP2009510123A (ja) 2009-03-12
MX2008004287A (es) 2008-10-23
PT1928464E (pt) 2014-07-10
EP1928464A4 (en) 2009-10-21
CN101309691A (zh) 2008-11-19

Similar Documents

Publication Publication Date Title
US20240165125A1 (en) Novel parenteral carbamazepine formulation
US11969470B2 (en) Topiramate compositions and methods of making and using the same
US20210196623A1 (en) Novel parenteral carbamazepine formulation
RU2574022C2 (ru) Анестезирующий состав
BRPI0809838B1 (pt) Composição, método para a estabilização do (s)-clopidogrel e uso de uma composição
BRPI0718541B1 (pt) Preparação líquida compreendendo um derivado de ciclodextrina eterificada e pimobendan, seus usos e seu processo de produção, e kit de partes
Shankar et al. Optimization of sulfobutyl-ether-β-cyclodextrin levels in oral formulations to enhance progesterone bioavailability
US5231089A (en) Method of improving oral bioavailability of carbamazepine
ES2901427T3 (es) Preparación líquida parenteral que comprende un compuesto de carbamato
AU2013200204B2 (en) Novel parenteral carbamazepine formulation
BR112019011914B1 (pt) Formulação líquida parenteral, composição injetável, e, método para preparar uma formulação líquida parenteral

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: LUNDBECK, INC. (US)

Free format text: NOME ALTERADO DE: OVATION PHARMACEUTICALS, INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]